Search
Elagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalMoreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. … In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801].
Cipaglucosidase alfa
go.drugbank.com/drugs/DB16708ApprovedInvestigationalin Pompe disease. … [A232955, A232960] In September 2023, the FDA also approved cipaglucosidase alfa for similar indications.[L49241]
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalgene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. … Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow.
Buserelin
go.drugbank.com/drugs/DB06719ApprovedInvestigationalIt is used in prostate cancer treatment.
Zuranolone
go.drugbank.com/drugs/DB15490ApprovedInvestigational[A260776,A260786] Zuranolone was designed with a pharmacological profile of a neuroactive steroid in mind while also possessing a pharmacokinetics profile of an oral, once-daily dosing formulation. … binding to a non-benzodiazepine site on the receptor.
Spectinomycin
go.drugbank.com/drugs/DB00919ApprovedVet approvedWithdrawnAn antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]
Mixtures: SPIRO COMP FORTE RAT100/20, SPIRO COMP FORTE RAT100/20Dotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawn[A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016. … Ga-68 dotatate has a high affinity for somatostatin-2 receptor and it is rapidly excreted from the nontarget sites which gives it an ideal candidate for imaging neuroendocrine tumors.
Atacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigational[L63797] Reducing BAFF- and APRIL-mediated signaling lowers production of galactose-deficient IgA1, an aberrant antibody whose deposition in the kidney drives IgA nephropathy. … [L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.
Buclizine
go.drugbank.com/drugs/DB00354Approved[A178102] In addition to the above conditions, buclizine has been studied in the treatment of migraine attacks and in the treatment of nausea and vomiting during pregnancy. [A178105, A178108] … [L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated.